164 related articles for article (PubMed ID: 33222517)
1. Generation of genetically tailored porcine liver cancer cells by CRISPR/Cas9 editing.
Elkhadragy L; Regan MR; M Totura W; Goli KD; Patel S; Garcia K; Stewart M; Schook LB; Gaba RC; Schachtschneider KM
Biotechniques; 2021 Jan; 70(1):37-48. PubMed ID: 33222517
[TBL] [Abstract][Full Text] [Related]
2. Description of CRISPR/Cas9 development and its prospect in hepatocellular carcinoma treatment.
Wu X; Ma W; Mei C; Chen X; Yao Y; Liu Y; Qin X; Yuan Y
J Exp Clin Cancer Res; 2020 Jun; 39(1):97. PubMed ID: 32487115
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.
Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M
Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495
[TBL] [Abstract][Full Text] [Related]
4. Effect of CRISPR Knockout of
Elkhadragy L; Dasteh Goli K; Totura WM; Carlino MJ; Regan MR; Guzman G; Schook LB; Gaba RC; Schachtschneider KM
Front Oncol; 2022; 12():904031. PubMed ID: 35669430
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
[TBL] [Abstract][Full Text] [Related]
6. A review of the literature on the use of CRISPR/Cas9 gene therapy to treat hepatocellular carcinoma.
Amjad E; Pezzani R; Sokouti B
Oncol Res; 2024; 32(3):439-461. PubMed ID: 38361756
[TBL] [Abstract][Full Text] [Related]
7. [Establishment of Cas9 stably expressed human hepatocellular carcinoma and cholangiocarcinoma cell lines].
Zuo CX; Bian XC; Yang ZL; Feng HL; Zhou FY; Liu YQ
Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):572-579. PubMed ID: 30139026
[No Abstract] [Full Text] [Related]
8. Co-delivery of Sorafenib and CRISPR/Cas9 Based on Targeted Core-Shell Hollow Mesoporous Organosilica Nanoparticles for Synergistic HCC Therapy.
Zhang BC; Luo BY; Zou JJ; Wu PY; Jiang JL; Le JQ; Zhao RR; Chen L; Shao JW
ACS Appl Mater Interfaces; 2020 Dec; 12(51):57362-57372. PubMed ID: 33301289
[TBL] [Abstract][Full Text] [Related]
9. lncRNA- RP11-156p1.3, novel diagnostic and therapeutic targeting via CRISPR/Cas9 editing in hepatocellular carcinoma.
Ali HS; Boshra MS; El Meteini MS; Shafei AE; Matboli M
Genomics; 2020 Sep; 112(5):3306-3314. PubMed ID: 32544548
[TBL] [Abstract][Full Text] [Related]
10. Targeted HBx gene editing by CRISPR/Cas9 system effectively reduces epithelial to mesenchymal transition and HBV replication in hepatoma cells.
Rawal P; Tripathi DM; Hemati H; Kumar J; Tyagi P; Sarin SK; Nain V; Kaur S
Liver Int; 2024 Feb; 44(2):614-624. PubMed ID: 38105495
[TBL] [Abstract][Full Text] [Related]
11. Cooperation between liver-specific mutations of pten and tp53 genetically induces hepatocarcinogenesis in zebrafish.
Luo J; Lu C; Feng M; Dai L; Wang M; Qiu Y; Zheng H; Liu Y; Li L; Tang B; Xu C; Wang Y; Yang X
J Exp Clin Cancer Res; 2021 Aug; 40(1):262. PubMed ID: 34416907
[TBL] [Abstract][Full Text] [Related]
12. Charge-reversal nanocomolexes-based CRISPR/Cas9 delivery system for loss-of-function oncogene editing in hepatocellular carcinoma.
Nie JJ; Liu Y; Qi Y; Zhang N; Yu B; Chen DF; Yang M; Xu FJ
J Control Release; 2021 May; 333():362-373. PubMed ID: 33785418
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9-Mediated Knock-Out of Kras
Lentsch E; Li L; Pfeffer S; Ekici AB; Taher L; Pilarsky C; Grützmann R
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31739488
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice.
Weber J; Öllinger R; Friedrich M; Ehmer U; Barenboim M; Steiger K; Heid I; Mueller S; Maresch R; Engleitner T; Gross N; Geumann U; Fu B; Segler A; Yuan D; Lange S; Strong A; de la Rosa J; Esposito I; Liu P; Cadiñanos J; Vassiliou GS; Schmid RM; Schneider G; Unger K; Yang F; Braren R; Heikenwälder M; Varela I; Saur D; Bradley A; Rad R
Proc Natl Acad Sci U S A; 2015 Nov; 112(45):13982-7. PubMed ID: 26508638
[TBL] [Abstract][Full Text] [Related]
15. Efficient generation of GHR knockout Bama minipig fibroblast cells using CRISPR/Cas9-mediated gene editing.
Wang R; Zhang JY; Lu KH; Lu SS; Zhu XX
In Vitro Cell Dev Biol Anim; 2019 Dec; 55(10):784-792. PubMed ID: 31456163
[TBL] [Abstract][Full Text] [Related]
16. Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma.
Kong H; Ju E; Yi K; Xu W; Lao YH; Cheng D; Zhang Q; Tao Y; Li M; Ding J
Adv Sci (Weinh); 2021 Dec; 8(24):e2102051. PubMed ID: 34665528
[TBL] [Abstract][Full Text] [Related]
17. Small extrachromosomal circular DNA harboring targeted tumor suppressor gene mutations supports intratumor heterogeneity in mouse liver cancer induced by multiplexed CRISPR/Cas9.
Guo T; Chen GQ; Li XF; Wang M; Liu KM; Yang XY; Liu SC; Feng YL; Liu PY; Lin H; Xie AY
Genome Med; 2023 Oct; 15(1):80. PubMed ID: 37803452
[TBL] [Abstract][Full Text] [Related]
18. Protocol for generation of humanized HCC mouse model and cancer-driver mutations using CRISPR-Cas9.
Zhu Y; Tahara SM; Tsukamoto H; Machida K
STAR Protoc; 2023 Dec; 4(4):102389. PubMed ID: 38103196
[TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas9-Mediated Gene Editing in Porcine Models for Medical Research.
Gao M; Zhu X; Yang G; Bao J; Bu H
DNA Cell Biol; 2021 Dec; 40(12):1462-1475. PubMed ID: 34847741
[TBL] [Abstract][Full Text] [Related]
20. In vitro genome editing activity of Cas9 in somatic cells after random and transposon-based genomic Cas9 integration.
Söllner JH; Sake HJ; Frenzel A; Lechler R; Herrmann D; Fuchs W; Petersen B
PLoS One; 2022; 17(12):e0279123. PubMed ID: 36584049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
